IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

被引：53

作者：

Emens, L. A. ^{[1
]}

Adams, S. ^{[2
]}

Barrios, C. H. ^{[3
]}

Dieras, V. C. ^{[4
]}

Iwata, H. ^{[5
]}

Loi, S. ^{[6
]}

Rugo, H. S. ^{[7
]}

Schneeweiss, A. ^{[8
]}

Winer, E. P. ^{[9
]}

Patel, S. ^{[10
]}

Henschel, V. ^{[11
]}

Swat, A. ^{[12
]}

Kaul, M. ^{[13
]}

Molinero, L. ^{[14
]}

Chui, S. Y. ^{[15
]}

Schmid, P. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA

[2] NYU, Langone Med Ctr, Sch Med, New York, NY USA

[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Invest Ctr, Porto Alegre, RS, Brazil

[4] Ctr Eugene Marquis, Med Oncol, Rennes, France

[5] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[6] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia

[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA

[8] Univ Hosp Heidelberg, German Canc Res Ctr, Heidelberg, Germany

[9] Dana Farber Canc Inst, Med, Boston, MA 02115 USA

[10] Genentech Inc, Med Oncol, San Francisco, CA USA

[11] Genentech Inc, Biostat, San Francisco, CA USA

[12] F Hoffmann La Roche, Clin Sci, Basel, Switzerland

[13] F Hoffmann La Roche, Canc Immunotherapy Clin Safety, Basel, Switzerland

[14] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA

[15] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA

[16] Queen Mary Univ London, Barts Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2244

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA16

引用

页码：S1148 / S1148

页数：1